Published in Ann Rheum Dis on April 10, 2006
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther (2012) 1.46
Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis (2011) 1.46
Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment. J Can Chiropr Assoc (2007) 1.34
A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int (2009) 0.98
Update on the treatment of ankylosing spondylitis. Ther Clin Risk Manag (2007) 0.93
Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther (2013) 0.90
Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis (2013) 0.89
New evidence on the management of spondyloarthritis. Nat Rev Rheumatol (2016) 0.87
Early diagnosis and treatment of ankylosing spondylitis in Africa and the Middle East. Clin Rheumatol (2012) 0.82
Developments in the scientific and clinical understanding of the spondyloarthritides. Arthritis Res Ther (2009) 0.81
How to translate basic knowledge into clinical application of biologic therapy in spondyloarthritis. Clin Dev Immunol (2013) 0.78
Toward a Mechanism-Based Approach to Pain Diagnosis. J Pain (2016) 0.78
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures]. Z Rheumatol (2014) 0.77
Old and new treatment targets in axial spondyloarthritis. RMD Open (2015) 0.77
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord (2015) 0.77
Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies. Ther Adv Chronic Dis (2015) 0.76
Coexisting ankylosing spondylitis and gouty arthritis. Clin Rheumatol (2007) 0.76
Infliximab in the treatment of ankylosing spondylitis. Biologics (2007) 0.76
Efficacy of SLZ and MTX (alone or combination) on the treatment of active sacroiliitis in early AS. Rheumatol Int (2009) 0.75
Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy. Core Evid (2008) 0.75
DWI and SPARCC scoring assess curative effect of early ankylosing spondylitis. Open Med (Wars) (2016) 0.75
Efficacy of an acquainted drug in the treatment of inflammatory low back pain: sulfasalazine under investigation. Drug Des Devel Ther (2016) 0.75
Sulfasalazine in undifferentiated spondyloarthropathies. Curr Rheumatol Rep (2007) 0.75
[Lessons learnt from 15 years of investigator-initiated trials on axial spondyloarthritis]. Z Rheumatol (2015) 0.75
[ASAS/EULAR recommendations for the management of ankylosing spondylitis : evaluation of the 2010 update in the German-speaking area]. Z Rheumatol (2013) 0.75
Survival of disease-modifying antirheumatic drugs used as the first antirheumatic medication in the treatment of ankylosing spondylitis in Finland. A nationwide population-based register study. Clin Rheumatol (2014) 0.75
Unanswered questions in the management of axial spondyloarthritis: an opinion piece. Clin Rheumatol (2014) 0.75
[Early therapy of axial spondyloarthritis and relevance of radiological progression]. Z Rheumatol (2012) 0.75
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum (1984) 20.51
The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum (1991) 11.66
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol (1994) 11.17
A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol (1994) 8.61
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum (2001) 4.57
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum (2005) 3.31
The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum (1984) 3.20
Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum (2006) 2.67
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum (1995) 2.16
[Evaluation of a German version of WOMAC (Western Ontario and McMaster Universities) Arthrosis Index]. Z Rheumatol (1996) 2.13
Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol (1988) 1.96
Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis (2005) 1.70
Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum (1999) 1.65
Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) (1999) 1.51
Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev (2005) 1.24
The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxford) (2005) 1.22
Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol (2002) 1.21
Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) (2000) 1.18
Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum (1988) 1.18
Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol (2004) 1.13
Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J (Clin Res Ed) (1986) 1.13
The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum (2004) 1.11
[Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]. Z Rheumatol (2003) 0.96
Ankylosing spondylitis and undifferentiated spondyloarthropathies: a clinical review and description of a disease subset with older age at onset. Curr Opin Rheumatol (2001) 0.96
Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis (2005) 0.91
Nucleotide sequence and exact localization of the neomycin phosphotransferase gene from transposon Tn5. Gene (1982) 13.62
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science (1999) 7.54
Nucleotide sequence of bacteriophage fd DNA. Nucleic Acids Res (1978) 7.25
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum (1998) 6.16
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med (1994) 5.80
Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science (1968) 5.76
Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet (1997) 5.44
Nucleotide sequence of the origin of replication of the Escherichia coli K-12 chromosome. Proc Natl Acad Sci U S A (1979) 5.31
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Nucleotide sequence of the gene ompA coding the outer membrane protein II of Escherichia coli K-12. Nucleic Acids Res (1980) 4.75
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet (1996) 4.20
Characterization of foot-and-mouth disease virus gene products with antisera against bacterially synthesized fusion proteins. J Virol (1986) 3.89
Nucleotide sequence and genome organization of foot-and-mouth disease virus. Nucleic Acids Res (1984) 3.81
The natural history of recovery for the healthcare provider "second victim" after adverse patient events. Qual Saf Health Care (2009) 3.79
Structure of the orgin of DNA replication of bacteriophage fd. Proc Natl Acad Sci U S A (1978) 3.52
Advocacy and compliance in genetic screening. Behavior of physicians and clients in a voluntary program of testing for the Tay-Sachs gene. N Engl J Med (1974) 3.47
Long-term pacing in sinus node disease: effects of stimulation mode on cardiovascular morbidity and mortality. Am Heart J (1988) 3.33
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Lactase haplotype diversity in the Old World. Am J Hum Genet (2000) 3.19
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA (1997) 3.17
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis (2009) 3.15
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum (1995) 3.10
Functional analysis of the internal translation initiation site of foot-and-mouth disease virus. J Virol (1990) 3.08
Cardiovascular evidence for an intermediate or higher metabolic rate in an ornithischian dinosaur. Science (2000) 2.98
Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries. Ann Rheum Dis (2004) 2.95
An assay for the detection of the DNA genome of hepatitis B virus in serum. J Med Virol (1982) 2.94
Nucleotide sequence and genome organisation of filamentous bacteriophages fl and fd. Gene (1981) 2.92
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum (2003) 2.91
How to diagnose axial spondyloarthritis early. Ann Rheum Dis (2004) 2.91
Interstitial pneumonia due to cytomegalovirus following low-dose methotrexate treatment for rheumatoid arthritis. Arthritis Rheum (1995) 2.88
A second protease of foot-and-mouth disease virus. J Virol (1986) 2.87
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology (2004) 2.81
Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature (2000) 2.81
H2O2 destruction by ascorbate-dependent systems from chloroplasts. Biochim Biophys Acta (1979) 2.78
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum (2003) 2.78
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis (2006) 2.72
[Rheumatology: Integration into student training--the RISA- Study. Results of a survey exploring the scale of education and training in rheumatology at German universities]. Z Rheumatol (2004) 2.69
Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol (1999) 2.65
An identified neuron mediates the unconditioned stimulus in associative olfactory learning in honeybees. Nature (1993) 2.65
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet (2000) 2.63
Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis (2009) 2.61
Structure of the FMDV translation initiation site and of the structural proteins. Nucleic Acids Res (1983) 2.58
Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J (2001) 2.52
Diurnal oscillation of amylolytic activity in spinach chloroplasts. Plant Physiol (1978) 2.47
Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res (2001) 2.45
Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci U S A (1994) 2.45
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 2.37
[Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire]. Z Rheumatol (1997) 2.34
A Bayesian approach for estimating values for prevalence and diagnostic test characteristics of porcine cysticercosis. Int J Parasitol (2004) 2.34
Gap junction formation between reaggregated Novikoff hepatoma cells. Proc Natl Acad Sci U S A (1974) 2.30
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis (2004) 2.26
Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect (2011) 2.23
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int (1999) 2.21
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum (2003) 2.20
Chlamydia and Borrelia DNA in synovial fluid of patients with early undifferentiated oligoarthritis: results of a prospective study. Arthritis Rheum (2001) 2.20
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2000) 2.19
Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum (1994) 2.19
An RNA transcribed from DNA at the origin of phage fd single strand to replicative form conversion. Proc Natl Acad Sci U S A (1978) 2.19
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum (1995) 2.16
Different genetic components in the Ethiopian population, identified by mtDNA and Y-chromosome polymorphisms. Am J Hum Genet (1998) 2.16
Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum (2011) 2.14
Q fever endocarditis in the United States. Ann Intern Med (1979) 2.12
Cloned structural gene (ompA) for an integral outer membrane protein of Escherichia coli K-12: localization on hybrid plasmid pTU100 and expression of a fragment of the gene. Mol Gen Genet (1980) 2.12
Huntington's disease: genetic heterogeneity in black African patients. S Afr Med J (2008) 2.12
Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr (1994) 2.06
Atrial versus ventricular pacing in sinus node disease: a treatment comparison study. Am Heart J (1986) 2.05